



< Back to results | 1 of 1

[Download](#) [Print](#) [Save to PDF](#) [Add to List](#) [Create bibliography](#)
Malaysian Journal of Medicine and Health Sciences • Open Access • Volume 18, Issue 2, Pages 341 - 343 • March 2023
Document type

Article • Bronze Open Access

Source type

Journal

ISSN

16758544

DOI

10.4783/mjmhs.19.2.48

Publisher

Universiti Putra Malaysia Press

Original language

English

View less

Intermittent EGFR-TKI Therapy is Associated with Durable Response in Advanced EGFR-Mutant NSCLC: A Case Report

Tan, Sin Nee^a ; Ibrahim, Aishah^a; Razak, Megat Razeem Abdul^a;Aziz, Muhammad Naimuddin Abdul^b; How, Soon Hin^b

^a Department of Internal Medicine, Hospital Tengku Ampuan Afzan, Jalan Tanah Putih, Pahang, Kuantan, 25100, Malaysia

^b Department of Internal Medicine, Sultan Ahmad Shah Medical Centre International Islamic University Malaysia, Jalan Sultan Haji Ahmad Shah, Bandar Indera Mahkota, Pahang, Kuantan, 25200, Malaysia

[View PDF](#) [Full text options](#) [Export](#)

Abstract

Author keywords

Sustainable Development Goals 2023

SciVal Topics

Abstract

Madam S, who diagnosed to have stage IV lung adenocarcinoma with exon 21 L858R point mutation (T3N2M1a) was admitted for massive pericardial effusion in April 2016. She was ECOG 4 on admission. Her ECOG improved to 1 after pericardial tapping and initiation of free sample erlotinib 100 mg daily. Repeated CT thorax post treatment showed the disease was partial responded. Due to financial constraints, she had never bought any EGFR-TKI. She was given a free sample of erlotinib intermittently

Cited by 0 documents

Inform me when this document is cited in Scopus:

[Set citation alert >](#)**Related documents**

Treatment Effectiveness and Tolerability of Long-term Adjuvant First- and Second-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor at Different Doses in Patients With Stage IIa-IIIB Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: A Retrospective Study

Ye, J.-R. , Chen, P.-H. , Chuang, J.-H.
(2022) *Frontiers in Surgery*

Lower starting dose of afatinib for the treatment of metastatic lung adenocarcinoma harboring exon 21 and exon 19 mutations

Chen, Y.-C. , Tsai, M.-J. , Lee, M.-H.
(2021) *BMC Cancer*

Effects of dose modifications on the safety and efficacy of dacomitinib for mutation-positive non-small-cell lung cancer

Corral, J. , Mok, T.S. , Nakagawa, K.
(2019) *Future Oncology*

[View all related documents based on references](#)

Find more related documents in Scopus based on:

[Authors >](#) [Keywords >](#)

for total of 12 months followed by intermittent afatinib supply for 2 years. Due to this limited supply, she took half doses of afatinib by cutting a 40 mg tablet once every few days to sustain the continuation of cancer treatment. No major side effects were observed and she remained ECOG 0 with good weight gain. Up to her last clinic visit in September 2021, her PFS was more than 5 years. Intermittent doses of EGFR-TKI may prolong PFS in patients with advanced EGFRm+ NSCLC who has limited treatment options. © 2023 Authors. All rights reserved.

Author keywords

Cancer; Epidermal growth factor receptor; Non-small cell lung adenocarcinoma; Resistant; Tyrosine kinase inhibitor

Sustainable Development Goals 2023 [\(i\)](#) New

SciVal Topics [\(i\)](#)

References (5)

[View in search results format >](#)

All

[Export](#) [Print](#) [E-mail](#) [Save to PDF](#) [Create bibliography](#)

- 1 Gallaher, J.A., Enriquez-Navas, P.M., Luddy, K.A., Gatenby, R.A., Anderson, A.R.A.

Spatial heterogeneity and evolutionary dynamics modulate time to recurrence in continuous and adaptive cancer therapies
[\(Open Access\)](#)

(2018) *Cancer Research*, 78 (8), pp. 2127-2139. Cited 133 times.

<http://cancerres.aacrjournals.org/content/78/8/2127.full-text.pdf>

doi: 10.1158/0008-5472.CAN-17-2649

[View at Publisher](#)

- 2 Yang, J.C.-H., Sequist, L.V., Zhou, C., Schuler, M., Geater, S.L., Mok, T., Hu, C.-P., (...), Wu, Y.-L.

Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: Post hoc analyses of the randomized LUX-Lung 3 and 6 trials
[\(Open Access\)](#)

[View PDF](#)

(2016) *Annals of Oncology*, 27 (11), pp. 2103-2110. Cited 148 times.

<https://www.journals.elsevier.com/annals-of-oncology>

doi: 10.1093/annonc/mdw322

[View at Publisher](#)

- 3 Tanaka, H., Taima, K., Itoga, M., Ishioka, Y., Baba, K., Shiratori, T., Sakamoto, H., (...), Tasaka, S.

Real-world study of afatinib in first-line or re-challenge settings for patients with EGFR mutant non-small cell lung cancer
[\(Open Access\)](#)

(2019) *Medical Oncology*, 36 (6), art. no. 57. Cited 18 times.

<http://www.springer.com/humana+press/journal/12032>

doi: 10.1007/s12032-019-1278-9

[View at Publisher](#)

- 4 Halmos, B., Tan, E.-H., Soo, R.A., Cadrelan, J., Lee, M.K., Foucher, P., Hsia, T.-C., (...), Cacereny, E.

Impact of afatinib dose modification on safety and effectiveness in patients with EGFR mutation-positive advanced NSCLC: Results from a global real-world study (RealGiDo) ([Open Access](#))

(2019) *Lung Cancer*, 127, pp. 103-111. Cited 55 times.

www.elsevier.com/locate/lungcan

doi: 10.1016/j.lungcan.2018.10.028

[View at Publisher](#)

-
- 5 Sheng, M., Wang, F., Zhao, Y., Li, S., Wang, X., Shou, T., Luo, Y., (...), Tang, W.

Comparison of clinical outcomes of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations after tyrosine kinase inhibitors treatment: A meta-analysis

(2016) *European Journal of Clinical Pharmacology*, 72 (1), pp. 1-11. Cited 57 times.

link.springer.de/link/service/journals/00228/index.htm

doi: 10.1007/s00228-015-1966-0

[View at Publisher](#)

✉ Tan, S.N.; Department of Internal Medicine, Hospital Tengku Ampuan Afzan, Jalan Tanah Putih, Pahang, Kuantan, Malaysia; email:christine0507@live.com

© Copyright 2023 Elsevier B.V. All rights reserved.

About Scopus

[What is Scopus](#)

[Content coverage](#)

[Scopus blog](#)

[Scopus API](#)

[Privacy matters](#)

Language

[日本語版を表示する](#)

[查看简体中文版本](#)

[查看繁體中文版本](#)

[Просмотр версии на русском языке](#)

Customer Service

[Help](#)

[Tutorials](#)

[Contact us](#)

ELSEVIER

[Terms and conditions](#) ↗ [Privacy policy](#) ↗

All content on this site: Copyright © 2023 Elsevier B.V. ↗ its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the Creative Commons licensing terms apply.

We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies ↗.



[View PDF](#)